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Positive and negative ion electrospray ionization (ESI) mass spectra of complexes of positively
charged small molecules (distamycin, Hoechst 33258, [Ru(phen)2dpq]Cl2 and
[Ru(phen)2dpqC]Cl2) have been compared. [Ru(phen)2dpq]Cl2 and [Ru(phen)2dpqC]Cl2 bind to
DNA by intercalation. Negative ion ESI mass spectra of mixtures of [Ru(phen)2dpq]Cl2 or
[Ru(phen)2dpqC]Cl2 with DNA showed ions from DNA-ligand complexes consistent with
solution studies. In contrast, only ions from free DNA were present in positive ion ESI mass spectra
of mixtures of [Ru(phen)2dpq]Cl2 or [Ru(phen)2dpqC]Cl2 with DNA, highlighting the need for
obtaining ESI mass spectra of non-covalent complexes under a range of experimental conditions.
Negative ion spectra of mixtures of the minor groove binder Hoechst 33258 with DNA containing
a known minor groove binding sequence were dominated by ions from a 1:1 complex. In contrast,
in positive ion spectra there were also ions present from a 2:1 (Hoechst 33258: DNA) complex,
suggesting an alternative binding mode was possible either in solution or in the gas phase. When
Hoechst 33258 was mixed with a DNA sequence lacking a high affinity minor groove binding site,
the negative ion ESI mass spectra showed that 1:1 and 2:1 complexes were formed, consistent with
existence of binding modes other than minor groove binding. The data presented suggest that
comparison of positive and negative ion ESI-MS spectra might provide an insight into various
binding modes in both solution and the gas phase. (J Am Soc Mass Spectrom 2004, 15, 1382–1391)
© 2004 American Society for Mass SpectrometryNucleic acids are increasingly the targets for drugtherapies. Drugs may interact directly with DNAinhibiting the growth of microorganisms or tu-
mors, or they may affect gene expression by interfering
with the binding of transcription factors (proteins) to
regulatory sequences of DNA [1]. It has been estimated
that in order to specifically target a unique regulatory
sequence within a gene in the human genome, eleven
DNA base pairs have to be recognized by a drug [2].
Consequently, efforts have been directed towards the
synthesis of novel compounds, often based on natural
products that interact non-covalently with extended DNA
sequences that have particular characteristics (e.g., AT-
rich promoters of genes). Drugs that bind non-covalently,
Published online August 27, 2004
Address reprint requests to: Prof. Margaret Sheil, Department of Chemistry
and Vice-Chancellors Unit, University of Wollongong, Northfields Avenue,
Wollongong, 2522, New South Wales, Australia. E-mail: msheil@uow.
edu.au.© 2004 American Society for Mass Spectrometry. Published by Elsevie
1044-0305/04/$30.00
doi:10.1016/j.jasms.2004.07.005but with relatively high affinity to DNA include minor
groove-binders and intercalators [1].
Minor groove-binders are crescent-shaped molecules
with potential H-bonding groups on their concave edge
[3]. They have a high affinity for AT-rich sequences, and
are often positively charged. Examples of this class of
drug are Hoechst 33258 and distamycin (Hc and Dm,
respectively; Figure 1a and b). Intercalators are planar
aromatic polycyclic compounds that slide between
stacked base pairs of the DNA double helix [1]. Substi-
tution on the aromatic rings can confer enhanced spec-
ificity to the drug-DNA interaction. For example, the
sugar moiety of daunomycin, a widely used antitumor
agent, can H-bond with atoms on the outside of the
helix [4].
As a first-pass evaluation of new drugs that may be
more sequence-selective in their interactions with DNA,
it will be useful to develop methods for rapid and
sensitive screening. Electrospray ionization mass spec-r Inc. Received April 14, 2004
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purpose. Several research groups have used ESI-MS to
assess the relative affinities and stoichiometries of
drugs that bind to DNA [5, 6]. Although many non-
covalent complexes have been studied by ESI-MS, ques-
tions remain as to the extent to which complexes
detected in the gas phase reflect the solution equilib-
rium position existing prior to injection into the mass
spectrometer [7–9]. There are at least three possibilities
to consider under a given set of experimental condi-
tions: (i) the abundances and stoichiometries of the
complexes are a snapshot of the complexes present in
solution, (ii) the complexes may not be stable during
ionization or transmission through the mass spectrom-
eter, and (iii) during the ionization/desolvation pro-
cess, new complexes that were not significant in solu-
tion may form in the gas phase.
There have been a number of ESI-MS studies in
which the drug-DNA complexes detected in the gas
phase were consistent with expectations derived from
solution studies [10–12]. For example, distamycin binds
in a 1:1 complex along AT-rich minor grooves of
double-stranded (ds) DNA, but NMR studies suggest
that it also binds in a head-to-tail fashion in a 2:1
complex with DNA [13]. Both of these stoichiometries
have been observed in ESI-MS experiments [10, 11, 14].
For ESI-MS to be developed as an effective screening
method for drug-DNA interactions, it is advantageous
to be able to compare the relative binding affinities of
drugs for various DNA sequences. This has been
achieved using competition experiments to compare the
affinities of intercalators for different DNA sequences
Figure 1. Structures of: the minor groove-bind
intercalators, (c) [Ru(phen)2(dpq)]Cl2, (d) [Ru(ph[6], and to compare the affinities of different minor
groove-binders for different DNA sequences [5, 11, 15].
Most ESI-MS investigations of DNA and drug-DNA
complexes have been carried out using negative ion
mode. This follows logically from the knowledge that
the phosphodiester backbone of DNA has a pKa  1,
and is therefore fully ionized under most experimental
conditions. There have been several recent reports of
ESI mass spectra of DNA acquired using positive ion
mode [14, 16–20]. Our own work has shown that
negative and positive ion ESI mass spectra of Dm/
dsDNA mixtures obtained under otherwise identical
experimental conditions were substantially different
[14]. In negative ion spectra, the most abundant ions
were from the dsDNA  2 Dm complex, whereas in
positive ion mode, the most abundant ions were from
the dsDNA  1 Dm complex. On the basis of these
observations and in-source collision-induced dissocia-
tion experiments (CID), we proposed that the complex
containing two Dm molecules is less stable when DNA
is positively charged.
In the present work, positive and negative ion ESI
mass spectra of complexes of 16 base pair dsDNA with
a number of positively charged drug molecules (Figure
1) have been compared to explore the extent to which
these effects are influenced by the nature of the binding
of the drug to DNA. One of the DNA strands used in
this study contained a central AAATA sequence that is
a high affinity site for Hoechst 33258 and distamycin
[21, 22]. Two relatively GC-rich DNA strands (D1 and
D3) were also used, which were therefore not predicted
to favor the minor groove-binding mode of interaction
) Hoechst 33258 (Hc), (b) distamycin (Dm); the
(dpqC)]Cl2.ers, (a
en)
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[Ru(phen)2dpq]Cl2 and [Ru(phen)2dpqC]Cl2 intercalate
between DNA base pairs, and were expected to bind to
these sequences [23]. The data presented suggest that
different binding modes may be differentially favored
in positive and negative ion ESI mass spectra.
Experimental
Chemicals
MilliQ water (Millipore, Billerica, MA) was used in all
experiments. Ammonium acetate and acetonitrile
(HPLC grade) were from Asia-Pacific Specialty Chem-
icals; Hoechst 33258 and distamycin A were from Sigma-
Aldrich (St. Louis, MO). DNA strands (D1: CCTCTCTG-
GACCTTCC/GGAAGGTCCAGAGAGG 9764.5 Da; D2:
GCTGCCAAATACCTCC/GGAGGTATTTGGCAGC
9763.5 Da; D3: CCTCATGGCCATGACC/ GGTCATG-
GCCATGAGG 9764.5 Da) were obtained from Gene-
works (Adelaide, Australia) as the trityl-on derivatives
and purified as previously described [24]. The concentra-
tion of single-stranded (ss) DNA was calculated using the
Oligonucleotide Properties Calculator [25].
Preparation of dsDNA-Drug Complexes
The formation of secondary structures within single
strands of DNA may introduce error in the concentra-
tions calculated from UV absorbance readings. In order
to ensure that equimolar amounts of complementary
strands were used in each experiment, single comple-
mentary strands were titrated against one another as
previously described [14]. The relative amounts of the
strands required to form 1:1 dsDNA calculated from
these titrations were then used in all experiments.
Distamycin and Hoechst 33258 were dissolved in 0.1 M
ammonium acetate, pH 8.5, to give stock solutions of 1.0
mM. All solutions were prepared just prior to use to
preclude the tendency of the drugs to aggregate in
solution over time. The appropriate volumes of comple-
mentary DNA strands were freeze-dried using a Savant
Speed-Vac (Milford, MA), then redissolved in 20 L of
0.1 M ammonium acetate, pH 8.5, giving a dsDNA
concentration of 1 mM. DsDNA was prepared by heat-
ing the complementary strands to 20 °C above their
melting temperature (obtained from Oligonucleotide
Properties Calculator [25]), in 0.1 M ammonium acetate,
pH 6.8, for 15 min and annealing by cooling slowly
overnight. An aliquot (60 L) of drug solution was
added to give the appropriate ratio of drug:dsDNA.
Mixtures of dsDNA with [Ru(phen)2dpq]Cl2 or
[Ru(phen)2dpqC]Cl2 were prepared as previously de-
scribed [15]. It should be noted that in our laboratory
we have established that no significant differences in
the relative abundances of drug-dsDNA complexes are
observed when the drugs are added either after or
during annealing of the DNA with the non self-comple-
mentary 16 mers used in these experiments [6, 14].Mass spectrometry
All mass spectra were acquired using a Micromass
(Wyntheshawe, UK) QTof2 mass spectrometer with a
Z-spray probe. The mass analyzer has an m/z range of
10 000. DNA ( drug) samples were diluted where
necessary with 100 mM ammonium acetate, pH 8.5,
giving a final concentration of dsDNA of 10 M. These
were injected directly using a Harvard Model 22 sy-
ringe pump (Natick, MA, USA) at a flow rate of 20 L
min1. Unless otherwise stated, ESI mass spectra were
acquired using a probe tip potential of 2600 V, a cone
voltage of 50 V, and the source block and desolvation
temperatures were 60 and 80 °C, respectively. The
transport and aperture were set to 2.0 and 13.0 (arbi-
trary units), respectively. In experiments where these
conditions were varied, details are given in the text. In
most experiments, spectra were acquired over the range
m/z 400–3000. Typically, 30 to 50 scans were summed to
obtain representative spectra. The data were calibrated
against a standard CsI solution (750 M) over the same
m/z range. The series of experiments reported here have
been repeated at least three times over a period of
several months and the differences reported here be-
tween positive and negative ion spectra are highly
reproducible.
Results and Discussion
Binding of Distamycin to dsDNA
In a previous work we showed that positive and
negative ion ESI mass spectra of 3:1 mixtures of Dm:
dsDNA (D2) acquired under otherwise identical exper-
imental conditions (cone voltage  50 V), provided
substantially different information concerning the rela-
tive abundances of the drug-DNA complexes [14]. The
most abundant ion in the positive ion spectrum was at
m/z 2049.9 corresponding to [dsDNA  1 Dm]5, while
the most abundant ion in the negative ion spectrum was
at m/z 1787.6 corresponding to [dsDNA  2 Dm]6.
Furthermore, when the cone voltage was varied, the
relative abundances of ions corresponding to either one
or two Dm molecules bound to dsDNA changed. At
cone voltages of 30–40 V, ions from dsDNA  2 Dm
predominated in positive ion ESI mass spectra [14].
These spectra were comparable with the negative ion
spectrum of the same dsDNA/Dm mixture acquired
when the cone voltage was 50 V.
We put forward two proposals to explain these
observations: (i) the similarity of the positive ion spectra
at 30–40 V and negative ion spectra at 50 V may be a
consequence of a difference in focusing of positive and
negative ions in the source, and/or (ii) the structure of
the complex containing 2 Dm molecules bound to
dsDNA may be intrinsically less stable when the DNA
is positively charged. The positive charge on the DNA
most likely resides on the nucleobases [20]; therefore
dsDNA sequences that favor binding of drugs with an
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the nucleobases would be expected to form complexes
that are less stable as positive ions in the gas phase. The
latter is also reflected in the fact that the positive ion
spectra are more sensitive to changes in cone voltage
and temperature than the corresponding negative ion
spectra of the same complexes.
In order to provide further understanding of these
initial observations, we have compared positive and neg-
ative ion ESI mass spectra of complexes of dsDNA with
other positively charged molecules: Hoechst 33258 (Hc;
minor groove binder) and two ruthenium-based interca-
lators (Figure 1). In our earlier experiments [14], we used
a desolvation temperature of 40 °C. Under these condi-
tions, positive ions in ESI mass spectra of dsDNA/dista-
mycin mixtures were associated with adducts that in-
creased in abundance as the concentration of distamycin
increased. In order to minimize these adducts we opti-
mized our conditions further in the present work. Figure
2 shows positive and negative ion ESI mass spectra of 3:1
Dm/D2 mixtures using source block/desolvation temper-
atures of 40/40 and 60/80 °C. The positive ion spectrum
(40/40 °C; Figure 2a) is comparable with our earlier
results using the same DNA sequence and experimental
conditions [14]. The most abundant ion in the spectrum
was at m/z 2049.9 corresponding to [D2 1 Dm]5. When
the temperatures were increased to 60/80 °C (Figure 2b),
this was still the most abundant ion, but adduct ions were
diminished, and the ion at m/z 1788.2 corresponding to
[D2  2 Dm]6 decreased in abundance. In contrast, the
negative ion ESI mass spectra of the 3:1 Dm/D2 mixture
Figure 2. Positive ion and negative ion ESI mass
with D2 obtained using different source block
desolvation 40/40 °C, positive ions; (b) Dm/D2, s
source/desolvation 40/40 °C, negative ions; (d) D
Hc/D2, positive ions, source block/desolvation te
block/desolvation temperatures 60/80 °C; (empty
D2  2 drugs.were very similar at the two temperatures (Figures 2c and
d), with the most abundant ion at m/z 1786.2 correspond-
ing to [D2 2 Dm]6. In negative ion spectra, adducts that
were associated with ions corresponding to Dm/D2 com-
plexes were less pronounced and were further decreased
at the higher desolvation temperature. Since this effect
was evident in both positive and negative ion spectra, the
following studies were carried out using source block and
desolvation temperatures of 60 °C and 80 °C, respectively.
A further point of comparison between the positive and
negative ion spectra is that the absolute abundance of ions
in the positive ion spectra was always higher than in the
negative ion spectra. This is generally true for many
different biological molecules and probably reflects differ-
ences in the ionization/transmission/detection of positive
versus negative ions rather than a difference in the relative
abundances of the complexes in solution.
Binding of Hoechst 33258 to dsDNA
Positive and negative ion ESI mass spectra of a 3:1 mixture
of Hc with dsDNA (D2) were acquired using a cone
voltage of 50 V and source block and desolvation temper-
atures of 60 °C and 80 °C, respectively. In contrast to the
results obtained for the Dm/dsDNA mixture, both the
positive and negative ion spectra of the 3:1 Hc/dsDNA
mixture show that the most abundant drug/dsDNA com-
plex contained one drug molecule (D2  1 Hc; ion at m/z
1697.5 in the negative ion spectrum and 1699.1 in the
positive ion spectrum; z 6 for both ions). In the negative
ion spectrum there were no significant ions from free
ra of a 3:1mixture of distamycin or Hoechst 33258
desolvation temperatures. (a) Dm/D2, source/
/desolvation 60/80 °C, positive ions; (c) Dm/D2,
2, source/desolvation 60/80 °C, negative ions; (e)
atures 60/80 °C; (f) Hc/D2, negative ions, source
) D2; (filled square) D2 1 drug; (filled diamond)spect
and
ource
m/D
mper
circle
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ence in this mixture of the 1:1 complex suggests that the
binding mode associated with this stoichiometry is highly
favored under these experimental conditions. In the pos-
itive ion ESI mass spectrum, ions from free DNA were
present, suggesting that the D2  1 Hc complex was less
stable when the DNA was positively charged. Since the
total ion counts were higher in positive ion spectra than in
negative ion spectra (e.g., 120 arbitrary units in Figure 2e
compared with 5 arbitrary units in Figure 2f), then any
ions from free dsDNA would have been clearly evident in
the negative ion spectra.
It is also of interest to note that in the positive ion
spectra of the 3:1 Hc/dsDNA mixture (Figure 2e) the
free dsDNA in this spectrum gave an ion where z  4,
which was not observed in the positive ion ESI mass
spectrum of the same dsDNA sequence in the absence
of drug acquired under the same experimental condi-
tions, nor was ion from z  4 observed in the spectra of
free dsDNA for all the sequences examined in this
study. The z  5 ion of the free dsDNA was also more
abundant than in the corresponding spectrum of
dsDNA in the absence of drug (data not shown). In
contrast for the negative ion spectra (Figure 2f) the
relative abundances of the major species (z 5, 6 and 7)
are similar for the free DNA (data not shown). One
would expect, given the relatively small size difference
between the dsDNA and drug-dsDNA, the same charge
state would be observed in each case. Hence, that in the
positive ion spectra of the dsDNA-drug complex (Fig-
ure 2e), ions from free DNA with z  4 and z  5 are
relatively more abundant than in the corresponding
spectrum of free dsDNA without drug added, suggests
that the ions from free dsDNA observed in the former
case result from dissociation of the drug-dsDNA com-
plex such as in eq 1 and 2:
[dsDNAHc]6↔ [dsDNA]5Hc (1)
[dsDNAHc]5↔ [dsDNA]4Hc (2)
A further difference between the negative and positive
ion spectra of the 3:1 Hc/dsDNA mixture is that in the
latter, there were ions of low abundance from D2  2
Hc (discussed below). Since the relative abundances of
ions from dsDNA complexes bearing one or two Dm
molecules were shown previously to vary with cone
voltage when the desolvation temperature was 40 °C
[14], we investigated the effects of changing cone volt-
age on ESI mass spectra of 3:1 mixtures of Hc with
dsDNA, and repeated our experiments using 3:1 mix-
tures of Dm with D2 [14], but using the higher desol-
vation temperature (80 °C). The effect of varying cone
voltage on positive and negative ion ESI mass spectra of
3:1 mixtures of either Dm or Hc with D2 (source block
and desolvation temperatures 60 and 80 °C, respec-
tively) is shown in Figure 3. The intensities of ions from
each complex were summed and plotted as a percent-age of the sum of intensities of all the ions in the
spectrum. It should be noted that in all positive and
negative ion ESI mass spectra acquired in this work, the
only ions of significant abundance were z  5 and 6,
with z  7 ions of low abundance. The results obtained
for the complex(es) with Hoechst 33258 were signifi-
cantly different from those obtained for the complexes
with distamycin. D2  1 Hc ions were more abundant
in both positive and negative ion spectra acquired at all
cone voltages from 30–60 V. Importantly, in the nega-
tive ion ESI mass spectra, the only significant ions
present were from D2  1 Hc, suggesting that this is a
stable complex. Solution and X-ray studies have shown
that Hoechst 33258 binds in 1:1 stoichiometry with
dsDNA containing (A/T)4 sequences [21, 26–28] span-
ning 5 base pairs. Since the phosphodiester backbone of
DNA is negatively charged in solutions above pH 2, ESI
mass spectra of negative ions are expected to be more
representative of the complexes found in solution if
there are no changes in the equilibrium during ioniza-
tion and transmission to the detector. The data shown
in Figure 3 are consistent with the persistence through
all stages of mass analysis of a stable 1:1 complex with
negatively charged DNA which has previously been
shown to be present by solution spectroscopic tech-
niques. Furthermore, the absence of ions from uncom-
plexed dsDNA over the cone voltage range 30–60 V
demonstrates the stability of this complex.
In contrast, in the positive ion spectra, there were
ions of low abundance from D2  2 Hc at all cone
voltages. Since both the DNA and Hc are expected to be
positively charged under these ionization conditions,
the binding of a second Hc molecule to the 16 mer DNA
is not likely to arise from non-specific ion pair forma-
tion in the gas phase. The positively charged D2 1
Dm, D2 2 Dm and D2  1 Hc complexes were less
stable when the cone voltage was increased than nega-
tively charged complexes. This effect is most likely the
result of electrostatic repulsion between the positively
charged DNA and the drug molecules.
The question as to whether the dsDNA  2 Hc com-
plex may have been present in solution prior to analysis
by ESI-MS or whether it was formed in the ionization
source needs to be considered. Although Hc binds with
high affinity to the minor groove of A/T sequences, it has
also been reported to bind as an intercalator at G/C
sequences [29]. In solution, if there were D2 molecules
with 1 Hc molecule bound in the minor groove at
AAATA, and a second Hc molecule intercalated between
a G-C base pair, then the ESI mass spectra presented here
(see Figure 2e and 2f) suggest that the putative intercala-
tive complex was not stable as negative ions under the
experimental conditions (since there were no significant
ions from D2  2Hc observed), but was stable under
ionization conditions where positively charged DNA was
generated. Although we have speculated that a second
Hoechst molecule might bind as an intercalator, other
binding modes might also be possible either in solution or
the gas phase. For example, some unwinding of the
1387J Am Soc Mass Spectrom 2004, 15, 1382–1391 POSITIVE AND NEGATIVE ION ESI-MS OF DRUG-DNA COMPLEXESpositively charged DNA may provide other potential sites
for H-bonding not otherwise accessible in fully base-
paired DNA. Clearly, other structural studies would be
required to confirm the presence of Hc bound to DNA in
a mode other than as a minor groove binder if such a
mode occurs in solution. Hoechst 33258/dsDNA com-
plexes with 2:1 stoichiometry have been observed previ-
ously in negative ion ESI mass spectra. Gabelica and
co-workers used an ESI ion trap mass spectrometer to
observe a 1:1 complex with a small percentage of 2:1
complex (c.a. 5%) with the 12 mer duplexes d(GGGG(A/
T)4GGGG)/d(CCCC(T/A)4CCCC). The 2:1 complex was
absent when the dsDNA was the self-complementary
Dickerson dodecamer d(CGCGAATTCGCG)2 [11, 12].
Fluorescence studies did not reveal the presence of the 2:1
complex in solution. They suggested that these results
supported the proposal that ESI-MS may be used as a
sensitive technique for detecting marginal binding modes.
If a second Hc molecule was bound as an intercalator to
D2, then this binding might be enhanced with sequences
of higher G/C content. The sequence selectivities of Hc for
2 different DNA sequences were compared using positive
and negative ion ESI mass spectrometry. Of particular
interest is the comparison between D2 and D1. D1 is
relatively GC-rich and does not contain a minor groove-
Figure 3. Relative abundances of ions in posit
distamycin or Hoechst 33258 with D2 acquired
from a complex were summed and expressed as
in the spectrum. (a) Hc, positive ions; (b) Hc, n
ions.binding site, while D2 contains a high affinity minor
groove site for Hc-binding. Figure 4 shows positive and
negative ion ESI mass spectra for a 3:1 mixture of Hc with
D1. These spectra can be compared with the spectra in
Figure 2e and f which show the positive and negative ion
ESI mass spectra for a 3:1 mixture of Hc with D2. The
spectra obtained for the mixtures of Hc with the two DNA
sequences are markedly different, and there are also
differences between the positive and negative ion spectra
for the same sequence. The negative ion spectra most
likely represent the components of the solution mixtures
in which the DNA is negatively charged, and comparison
of the spectra for the 3:1 mixtures of Hc with D1 or D2
reveal clear binding differences. The negative ion ESI mass
spectrum (Figure 2f) of the D2 mixture (harboring the high
affinity minor groove-binding site) shows only ions from
D2  1 Hc consistent with solution studies [21, 26–28].
The negative ion spectrum of the 3:1 Hc:D1 mixture
(Figure 4b) contains no significant ions from D1  1 Hc;
the most abundant ions are from free DNA, with an ion of
significant abundance from D1  2 Hc. The presence of
ions from the D1 2Hc suggests that Hc may be bound to
D1, a sequence with no minor groove binding site, in a
different binding mode, possibly as an intercalator [29].
Alternatively, in the absence of a high affinity minor
d negative ESI mass spectra of 3:1 mixtures of
different cone voltages. The intensities of ions
rcentage of the sum of the intensities of all ions
e ions; (c) Dm, positive ions; (d) Dm, negativeive an
using
a pe
egativ
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site, 2 Hc molecules may be able to bind in a more
sterically or electrostatically favorable arrangement.
The positive ion spectrum shows ions from both D1 
1 Hc and D1  2 Hc suggesting that the structure of D1
 2 Hc (the only complex observed in the negative ion
spectrum) was not as stable when the DNA was posi-
tively charged. This appears at first glance to be at odds
with the observations for D2 where D2 2 Hc occurred
only in positive ion ESI mass spectra (Figure 2e). This
apparent discrepancy might be explained if D1  2 Hc
complexes involve intercalation or another alternate
mode of binding for both Hc molecules, while D2  2
Hc complexes involve one Hc molecule binding in the
minor groove and one via an alternate mode. In that
case for the D1  2 Hc complex, one of the additional
Hc molecules would have been bound in a position that
Figure 4. Positive and negative ion ESI mass s
Hc:D1, positive ions; (b) 3:1 Hc:D1, negative i
square) D1  1 Hc; (filled diamond) D1  2 Hc
Figure 5. Summary of observations from positi
of Hoechst 33258 with either D1 or D2. (a) Obser
Observations from positive ion spectrum of 3:1
of 3:1 Hc: D1, (d) Observations from negative iomade it less stable when the DNA was positively
charged. This possibility is depicted schematically in
Figure 5 where it is assumed for simplicity that the
second binding mode is intercalation. To our knowl-
edge, there have been no X-ray or solution structures
determined for complexes of Hoechst 33258 with D1 or
similar sequences.
These experiments do not exclude the possibility that
the so-called “second binding mode” is simply non-
specific aggregation of positively charged drugs with
DNA during ionization and evaporation of the electro-
spray droplets. However, that the ESI mass spectra for
3:1 mixtures of Hc with dsDNA of the two sequences
were substantially different suggests that these data are
a function of different structures formed in solution (or
in the gas phase) with D1 and D2 rather than non-
specific binding.
a of mixtures of Hoechst 33258 with D1. (a) 3:1
filled circle) ssDNA; (empty circle) D1; (filled
d negative ion ESI mass spectra of 3:1 mixtures
ns from positive ion spectrum of 3:1 Hc: D1. (b)
2, (c) Observations from negative ion spectrum
ectrum of 3:1 Hc: D2.pectr
ons; (
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Previously, it was shown that dsDNA sequence
preferences for binding of [Ru(phen)2dpq]Cl2,
[Ru(phen)2dpqC]Cl2 and [Ru(phen)2dppz]Cl2 could be
determined by comparing negative ion ESI mass spec-
tra of the complexes with different DNA sequences [15].
NMR studies show that these ligands intercalate be-
tween DNA base pairs [23]. In the present work, we
have focused on the interactions of [Ru(phen)2dpq]Cl2
and [Ru(phen)2dpqC]Cl2 with D3. Since these com-
pounds both contain Ru2 they are expected to be
attracted to the negatively charged phosphodiester
backbone of DNA. Consequently, any significant differ-
ences in binding may arise from variations in their
relative binding affinities (or sequence preferences) for
intercalation.
[Ru(phen)2dpq]Cl2 and [Ru(phen)2dpqC]Cl2 were
mixed with D3 in the ratios 1:1, 1.5:1, 3:1 and 6:1 (drug:
dsDNA). Figure 6 shows negative and positive ion ESI
mass spectra of the 3:1 mixtures. When ESI mass spectra
were acquired in positive ion mode (Figures 6a and b),
there were no significant ions present from any dsDNA-
drug complex in any of the mixtures; the only ions
observed were from free D3 or single strands from D3. In
contrast, the negative ion spectra (Figures 6c and d)
showed ions from dsDNA-drug complexes with the num-
ber of drug molecules bound to DNA increasing with
increasing amounts of [Ru(phen)2dpq]Cl2 and
[Ru(phen)2dpqC]Cl2 present in the mixtures. The most
abundant (negative) ions from dsDNA-drug complexes in
the [Ru(phen)2dpq]Cl2/D3 mixture were from dsDNA 
1 [Ru(phen)2dpq], while for [Ru(phen)2dpqC]Cl2/D3 mix-
tures the most abundant negative ions were from dsDNA
 2 [Ru(phen)2dpqC].
Since DNA is negatively charged in solution and these
Ru-based compounds have been shown to bind to DNA
Figure 6. Positive and negative ion ESI ma
[Ru(phen)2(dpqC)]Cl2 with D3. (a) 3:1
[Ru(phen)2(dpqC)]Cl2:D3, positive ions; (c) 3
[Ru(phen)2(dpqC)]Cl2:D3, negative ions. (empty
D32 drugs; (cross) D33 drugs; (empty squarusing other techniques [23], the negative ion spectra are
likely to provide a more accurate picture of the complexes
present in solution. Furthermore, previously it has been
shown that complexes of well-characterized intercalators
with dsDNA can be detected in positive and negative ion
ESI mass spectra [6, 14]. It seems likely that dissociation of
these compounds occurred during/after formation of pos-
itively charged DNA in the ionization source. A similar
observation was made for complexes of 16 base pair
dsDNA complexed with (positively charged) ethidium
bromide (EtBr). Positive ion ESI mass spectra of 3:1
mixtures of ethidium bromide with DNA showed no ions
from dsDNA-EtBr complexes. In contrast, negative ion
spectra showed ions for free dsDNA and complexes
containing 1–5 bound EtBr molecules (data not shown).
This compound is known to intercalate into DNA and is
used extensively in molecular biology laboratories for
DNA staining [1]. Thus while we have speculated that the
second Hc molecule observed to bind in the positive ion
spectra may result from partial intercalation, the compar-
ison with a classical intercalator such as ethidium bromide
supports the notion that the nature of the binding of the
second Hc may be in fact more complex.
Furthermore, while no ions from dsDNA-drug com-
plexes were observed in positive ion spectra of the
Ru-based intercalators with dsDNA, the presence of the
z  4 ion from dsDNA in these spectra (Figure 6) may
indicate that the complex dissociates during ionization/
transfer to the gas phase according to dissociation
channels similar to those proposed for Hc (eq 1 and 2).
Conclusions
The experiments reported here indicate that comparison
of positive and negative ion ESI mass spectra might reveal
information concerning the binding modes of drug mole-
ectra of mixtures of [Ru(phen)2(dpq)]Cl2 or
hen)2(dpq)]Cl2:D3, positive ions; (b) 3:1
u(phen)2(dpq)]Cl2:D3, negative ions; (d) 3:1
) D3; (filled square) D31drug; (filled diamond)
 4 drugs.ss sp
[Ru(p
:1 [R
circle
e) D3
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spectra of Hoechst 33258 with DNA containing a known
minor groove binding sequence, a possible alternative
binding mode was proposed to occur. The binding of
Hoechst 33258 to a sequence that did not allow minor
groove binding supported the hypothesis that an alterna-
tive binding mode was possible. This alternate binding
mode appears to be different to both the side by side
binding that occurs when two molecules of distamycin
bind to DNA and to classical intercalation since both
modes are appear to be unstable under positive ion
ionization conditions.
Positive charges in ESI mass spectra of DNA are
thought to reside on the nucleobases [30]. The proton
affinities of dA, dC, and dT are 233.6, 233.2, and 224.9
kcal/mol, respectively. Therefore, complexes of posi-
tively charged compounds with DNA will be unstable
when positive ions are formed in the mass spectrometer
if their (solution) sequence preference places them in a
position where there will be unfavorable interactions
with positive charges generated on nucleobases in the
ionization source. Furthermore, where there is more
than one binding mode available for a drug, the struc-
tures of the complexes detected in positive ion spectra
may be those in which the positive charge on the drug
can be stably accommodated after binding to DNA. For
example, no complexes of dsDNA with either
[Ru(phen)2dpqC] or [Ru(phen)2dpq] were observed in
positive ion spectra, although these compounds are
known to bind to DNA. In order to test this proposal it
will be necessary to determine an X-ray structure of
complexes such as D3/ [Ru(phen)2dpqC] to determine
which atoms of the drug molecule are in proximity to
atoms on DNA nucleobases that become positively
charged in the ionization source.
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